Cancer therapeutics have come a long way in a short time span, leading to significant paradigm shifts in drug discovery. The emergence of checkpoint inhibitors that target T lymphocytes has dramatically altered cancer treatment, availing a plethora of new opportunities that leverage the immune system either as a monotherapeutic, or increasingly within combinatorial treatments, in the clinical management of patients. Ivan Gladwyn-Ng at Taconic Biosciences reveals how a review of the past, present, and future of humanised models to support immuno-oncology demonstrates how these essential tools are helping researchers in their quest to advance cancer therapies.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2020/02/Modelling-Cancer-for-Immuno-oncology.pdf” width=”100%” height=”900px” style=”border:0;”]